Nefecon, the gut-targeted formulation of budesonide, designed to modulate gut-associated lymphoid tissue and suppress the synthesis of galactose-deficient IgA1, has shown significant efficacy in reducing proteinuria and preserving renal function in patients with IgA nephropathy (IgAN). However, real-world evidence regarding its efficacy and safety as an initial therapeutic option in the broader IgAN population remains limited.
Zhao et al. (Wed,) studied this question.